Inhibrx – OX40 Agonist Shows Early Benefit

Summary Inhibrx Biosciences reported interim Phase 2 data for INBRX-106 in combination with Keytruda in first-line head and neck squamous cell carcinoma (HNSCC), suggesting potential costimulatory benefit beyond PD-1 monotherapy. What Happened The company released early Phase 2 clinical data evaluating INBRX-106, an OX40 agonist…